Revealing the crosstalk between nasopharyngeal carcinoma and immune cells in the tumor microenvironment

Jianyun Jiang1,2,3 and Hongmei Ying1,2,3*

Abstract
Nasopharyngeal carcinoma (NPC) arises from the epithelial cells located in the nasopharynx and has a distinct geographic distribution. Chronic Epstein-Barr virus (EBV) infection, as its most common causative agents, can be detected in 100% of NPC types. In-depth studies of the cellular and molecular events leading to immunosuppression in NPC have revealed new therapeutic targets and diverse combinations that promise to benefit patients with highly refractory, advanced and metastatic NPC. This paper reviews the mechanisms by which NPC cells to circumvent immune surveillance and approaches being attempted to restore immunity. We integrate existing insights into anti-NPC immunity and molecular signaling pathways as well as targeting therapies in anticipation of broader applicability and effectiveness in advanced metastatic NPC.

Keywords: Nasopharyngeal carcinoma, Tumor microenvironment, Immune cell, Immunotherapy

Background
The stroma of NPC is densely infiltrated by immune cells and is therefore likely to elicit a specific adaptive antitumor response [1–4]. Conventional chemotherapy (IMRT singly or in combination with chemotherapy) is the standard treatment paradigm for early-stage NPC or locoregionally advanced NPC but is less effective in advanced recurrent or metastatic NPC (R/M NPC) due to nonspecific clinical signs and lack of early detection biomarkers [5]. Recently, immunotherapy in combination with chemotherapy is expected to be the first-line treatment option to extend progression-free survival of patients with R/M NPC [6, 7].

Recent single-cell sequencing delineates complex TME and crosstalk between cells. Persistent EBV infection decreases the immunogenicity of cancer cells and alters the tumor microenvironment [5, 8–10]. Although many factors that promote immune escape have been illuminated, treatment strategies to retrieve antitumor immunity have not been achieved. This review will systematically describe the ability of NPC to reprogram the TME through molecular and cellular interactions and shed light on the cutting-edge immunotherapies currently underway.

Immune landscape of EBV-NPC
CD45+ immune cells existing in the NPC microenvironment mainly included T cells, B cells, natural killer cells (NK cells), and myeloid-derived suppressor cells (MDSCs) [11]. EBV in NPC cells exists in a type II latent state, encoding very limited non-coding RNAs and onco-geric proteins to reduce immunogenicity [12, 13], so
lymphocytes fail to kill tumor cells despite the presence of massive infiltration in the tumor microenvironment (TME) (Fig. 1). Controlling persistent EBV infection and unlocking the potential of immunity requires induction of stable and effective T cell pools to prevent a recurrence. TCR analysis has confirmed the dynamic transition of T cells from activation to dysfunction [11], which is triggered early in tumor initiation, even before malignant transformation [14, 15]. IFN-induced genes are also upregulated by EBV infection, including ISG15, IFI6, IFI44L, and IFITM3. Long-term and sustained IFN activation may lead to T cell response failure [16, 17]—a mechanism that requires further investigations. EBV-infected tumor cells are usually resistant to NK cell surveillance. There have been many studies examining the role of NK cells on EBV-infected B cells, but for now, the studies on the interaction between NK cells and NPC cells is not well understood [18–20]. However, it is worth noting that tonsil NK cells may have an important effect on limiting EBV infection and subsequent carcinogenesis as the tonsils are the direct entry point for EBV [21].

Whole-exome sequencing studies have shown that misregulation of NF-kB signaling pathway is a major oncogenic driver of NPC. Besides, radiation-resistant nasopharyngeal carcinoma tissues often exhibit high levels of cancer-associated fibroblasts (CAFs), which produce substances that affect the biological behavior of nasopharyngeal carcinoma [22]. Fibroblast growth factor 2 (FGF2), secreted by CAFs, is the upstream molecule of the PI3K/AKT signal pathway. Aberrantly activated FGF signaling is involved in the accumulation of tumor-infiltrating MDSCs and M2-TAMs [23], remodeling the metabolism of NPC cells and promoting metastasis. Therefore, FGF2/FGFR2 may be a crucial target in NPC [24]. FGF/FGFR inhibitors promote further activation and infiltration of effector T cells into the TME by normalizing tumor vasculature. In this context, the combination of FGFR-targeted drugs with ICI may serve as an attractive therapeutic option to overcome to some extent the resistance to immunotherapy in NPC [25].

The increased B cells in NPC TME is conducive to the formulation of tertiary lymphoid structures (TLSs), in
which B cells cooperate with T cells in maturation and activation [26, 27]. A high expression of B cell-related markers is associated with prolonged progression-free survival in NPC patients [11]. In addition, plasma cells are present within the TLSs, and deposits of many types of antibodies can be detected on tumor cells. TLSs have been found to produce an effective adaptive immune response like SLOs and are associated with longer survival in NPC patients [28]. Several approaches are being developed to induce TLSs formation using chemokines, cytokines, antibodies, antigen-presenting cells (APCs), or synthetic scaffolders [29].

Macrophages infiltrating the NPC microenvironment present an M1-M2 coupling paradigm and express both M1 and M2 markers [11]. Multicellular communication between macrophages and lymphocytes are prevalent but still unclear due to dynamic functional changes. Also, NPC cells can inhibit DCs maturation and IL-12 production, and promote the production of immunosuppressive factor IL-10 [30]. LAMP3+DCs are highly mature DCs that highly express suppressor proteins, produce multiple cytokines to recruit regulatory T cells (Tregs), and inhibit effector T cell functions [31]. The role of highly enriched MDSCs in cancer progression remains poorly understood. Functional analyses at both cellular level and animal level are necessary to clarify their modulatory potentials in NPC. Regulatory T cells (Tregs) will be recruited into the tumor microenvironment by substances secreted by the tumor and also assist the tumor to escape from immune surveillance. Tregs express immune checkpoint molecules in direct contact with other cells (e.g., LAMP3+DCs), secret suppressive cytokines into the microenvironment, and secret specific IDO to participate in metabolic reprogramming [32] (Fig. 1).

NPC crosstalk leading to immune escape

Direct cell–cell contact

i. Expression of inhibitory ligands/receptors

Depleted T cells are characterized by overexpression of checkpoint molecules (e.g., PD-1, CTLA4, LAG3, TIM3, and TIGIT). Thus, depletion program might be elicited by EBV-mediated crosstalk with NPC cells [33–35]. EBER1 [36], miR-BART6-3p [37], circBART2.2 [38], and LMP1 [33] encoded by EBV activate the RIG-I pathway and upregulate PD-L1 expression on NPC, thus affecting T cell immune recognition and ultimately promoting immune escape. EBV-miR-BART11 and EBV-miR-BART17-3p promote the transcription of PD-L1 by targeting FOXP1 and PBRM1, respectively [39]. Immune checkpoint molecules expressed by NPC cells or immune cells constitute the rationale for the development of checkpoint inhibitor therapies, such as pembrolizumab, nivolumab, and camrelizumab, which are now used as standard second-line agents in the management of R/M NPC [7, 40]. Unfortunately, NPC cells can use alternative mechanisms, such as upregulating TIM-3 and LAG-3 to maintain immunosuppression [41, 42].

NKs can target EBV-infected cells that are in the lytic replication phase and maintain the homeostasis of the host immune system [43, 44]. A recent study found that LMP2A inhibited NK cell function through platelet aggregation by platelet factor 3, which offers a novel candidate for the development of NK cell immunotherapy [45]. EBV miRNAs have been confirmed to mediate the escape of NK cell killing by down-regulating NKG2D ligand and target pro-apoptotic proteins such as PUMA to resist NK cell cytotoxicity [46–49]. Elevated pro-inflammatory cytokines IL-18 can also be mediated by EBV to induce PD-1 expression responsible for the functional exhaustion of NK cells [50].

ii. HLA epitopes mutation

Somatic MHC class I gene aberrations occur in greater than one-third of EBV-associated NPC [51], which may allow these NPC cells to evade the immune response [52]. Moreover, these alterations were significantly associated with prognostic indicators of patients. MHC class II gene alterations may also mediate the immune escape in NPC [53]. The mechanism by which MHC-I or MHC-II aberrations or both directly contribute to immune evasion remains to be determined. EBV-encoding miRNAs impair MHC class I/II- restricted antigen presentation [54] and reduce surface expression of HLA-B molecules, which are major MHC-I restriction elements of EBV-specific CD8+ T cell responses [55]. LMP2A also down-regulates HLA-A/B/C and MIC-A/B expression through promoter hypermethylation, thereby inhibiting T and NK cell responses [56].

Indirect interactions between cells

i. Exosomes

Exosomes can play a key role as messengers to mediate cellular communication and deliver components to receptor cells. NPC cells indoctrinate exosomes (NPC-Exo) containing LMP1, and miRNAs to the TME, resulting in immune escape from host surveillance [32, 57] (Fig. 2). Mrizak et al. first identified the unique immunomodulatory ability of NPC-Exos to recruit Tregs into the microenvironment via the chemokine CCL20 and to recruit conventional CD4+ T cells and induce their conversion to inhibitory Tregs [32]. Exosomal LMP1 effectively activates oncogenic NF-kB and MAPK/Akt signaling [58, 59] and leads to T cell anergy [60]. They also severely inhibit the maturation of
B lymphocytes into plasma cells [61]. In addition, exosomal LMP1 activates CAFs and then promotes tumor progression through stroma-tumor inter-relationships [62]. IL-6 is an inflammatory factor that promotes the occurrence of tumors. NPC-Exos show a more robust ability to induce IL-6 secretion from macrophages than exosomes derived from normal epithelial cells, and this difference is likely due to the different cargoes loaded [63].

The microenvironment characterized by hypoxia increases the level of exosomal miR-24-3p in NPC cells, thus enhancing the inhibitory effect on T cell proliferation and differentiation, and causing Treg-mediated suppression though inhibition of FGF11 [64]. In addition, MHC-I MICA and MICB ligands are likely to be removed by tumor cells into exosomes to evade recognition and clearance by NKG2D-activating receptor on natural killer cells and patrolling cytotoxic CD8+ T cells [65]. Understanding the specific substances that tumor cells select into exosomes can help reveal the mechanisms of immune evasion. As for NPC-lncRNAs, lncRNA-LINC00460 and lncRNA PVT1 have been involved in glucose metabolism and susceptibility to T cell-mediated lysis of NPC cells [66–68]. LncRNA TP73-AS1 is carried from NPC cells by extracellular vesicles and is associated with the polarization of macrophage toward the M2 phenotype [69]. TP73-AS1 is associated with a variety of cancers, so presumably, TP73-AS1 may be an NPC potential target [70–72].

Exosomal Galectin-9 produced by NPC cells stimulates the differentiation of MDSC by inhibiting STING signaling pathway and then upregulating a subset of cytokines, such as IL-1, IL-6, CX3CL1 and CCL22 [73–75]. Moreover, it can affect NK cell control of EBV and participate in M2 polarization of macrophages [76–78]. The binding of Galectin-9 to TIM-3 induces apoptosis in tumor cells, but for those PD-1-positive cells, PD-1 may inhibit this process. This is a novel mechanism of PD-1 that leads to exhausted T cell persistence [79]. High levels of soluble and exosomal Galectin-9 correlate with a higher risk of recurrence in NPC [80]. Unlocking more biological functions of the Galectin-9 will enable us to identify its possibilities as a circulating marker and as a new target for immune checkpoint inhibitor therapy.

Recently, PD-L1 has been reported to be highly expressed in tumor-derived exosomes (Exo-PD-L1) that can directly contact T cells [81, 82]. Moreover, Exo-PD-L1 will suppress distant (e.g., spleen) T cells or even circulating T cells. It has been considered as a biomarker for HNSCC disease progression and clinical staging [83], as well as a predictor of immunotherapy [84]. It's reasonable to assume that in addition to EBV DNA, PD-L1 in exosomes also has predictive value as a liquid biopsy method. Notably, Exo-PD-L1 can be secreted in large amounts by irradiated tumor cells, which suggests that the immunomodulatory effects of tumor-derived exosomes in response to radiotherapy and a synergistic therapeutic effect of radiotherapy and immune checkpoint inhibitors.
iii. Metabolic mediators

There are a growing number of studies on metabolic reprogramming and immune evasion of NPC cells, but the majority have focused only on one side of the story. Regarding the competition for nutrients, NPC cells have a greater competitive advantage over immune cells for glucose, thus inhibiting the activity of immune cells [93, 94] (Fig. 3). LMP1 activates multiple cellular signaling pathways in NPC cells [95], among which the FGF/FGFR signaling pathway is activated to increase glucose and glutamate uptake, LDHA activity, lactate generation, and the level of hypoxia-inducible factor 1 (HIF-1α) [96]. Interestingly, glutamine deprivation enhanced glucose uptake by tumor cells, thereby reducing the amount of glucose available to immune cells, suggesting that glutamine may be the limiting factor in TME, rather than glucose. Selective cellular partitioning of nutrients could be used to develop novel therapies that target specific cell types as well as more accurate imaging strategies [97].

Given the high metabolic rate of cancer cells, lactic acid secreted by tumors is an important metabolite in TME [98]. High concentrations of lactate interfere with the metabolism of immune effector cells, promote conversion to an immunosuppressive phenotype, inhibit the release of pro-inflammatory cytokines, and activate CAFs.

Fig. 3 Aerobic glycolysis in NPC cells. LMP1 secreted by EBV enhances glucose consumption and lactate generation in NPC cells. Increased glucose consumption in the tumor cells leads to immune cell starvation. EBV (LMP1) leads to the accumulation of fumarate in the tricarboxylic acid cycle (TCA), which inhibits the expression of RIP3 and protects NPC cells from TNF-induced necrotizing apoptosis. GLUT1: glucose transporter 1, OAA: Oxaloacetic acid, a-KG: α-ketoglutarate, LDH: lactate dehydrogenase, G6PD: glucose-6-phosphate dehydrogenase.
to produce VEGF to stimulate angiogenesis [99–102]. Similarly, lipid metabolism also affects T cell function and the expression of inhibitory receptors [103]. Fatty acids (FAs) have been reported to facilitate the malignant behavior of tumor cells [104, 105]. Virus-encoded proteins reprogram cellular metabolism and promote the optimal generation of progeny virion generation [106]. The LMP1 leads to the accumulation of the metabolite fumaric acid, inhibiting the expression of RIP3 and protecting NPC cells from TNF-induced necrosis secreted by macrophages [107]. Targeting lipid metabolism may be a novel idea worthy of further study in the treatment of NPC.

Other oncological metabolites such as adenosine, kynurenine, and tryptophan can affect tumor immunity. Elevated HIF enhances the expression of external nucleosidase (CD39 and CD37), which convert ATP to adenosine, a metabolite of immunosuppressant mediators. Extracellular adenosine attenuates T cell adhesion and cytotoxicity through A2a and A3 adenosine receptors [108, 109]. IDO is highly expressed in NPC, and as previously mentioned, IDO is an immunosuppressive metabolite that catabolizes intracellular tryptophan to produce kynurenine. The increased kynurenine in the microenvironment acts on the AHR signaling axis of the naïve T cells, causing them to differentiate into Tregs [110]. In addition, IDO can directly activate Treg cells via the PD-1/PD-L1 binding. There are clinical trials actively investigating IDO inhibitors in combination with immunotherapy (NCT03823131) or other chemotherapies [111]. Other metabolic inhibitors such as 3-bromopyruvate and oxalate inhibit hexokinase (HK) and LHDA activity and activate macrophage and T cell in animal models including NPC [112, 113]. Therefore, the combination of small molecule drugs or antibody intervention drugs that target metabolic processes with immunotherapy agents may become a potential clinical choice.

**Augmenting or rescuing immunity in NPC**

The combination of radiotherapy and chemotherapy (gemcitabine, cisplatin, and fluorouracil) is the conventional treatment paradigm for NPC but face obstacles in treating locoregional advanced or metastatic NPC. It is urgent to seek more effective strategies with greater efficacy and less toxicity [114, 115]. Several approaches including checkpoint inhibitors and cell-based immunotherapy have been used to revitalize the depleted immune cells in the NPC TME (Table 1).

**Checkpoint inhibitors**

Checkpoint inhibitors act on chronically stimulated T cells to reverse the fixed “exhaustion” state. About one-third of NPC cells and half of immune cells express PD-L1 [118, 119], and the difference in expression ratios among patients correlated strongly with the clinical effect of anti-PD-1/PD-L1 immunotherapy. NCI-9742 is the first completed report on the clinical response of Nivolumab in R/M NPC patients with an ORR of 20.5% and a 1-year OS rate superior to historic data in similar populations [40]. Like Nivolumab, pembrolizumab demonstrated a favorable antitumor activity in R/M NPC patients [7]. However, more impressive is the median PFS of 11.7 months with the addition of Toripalimab to GP chemotherapy as a first-line treatment for R/M NPC patients [6]. RATIONAL-309 studies (NCT03924986, Phase III) also showed that by April 2022, Tislelizumab plus GP significantly extended the median PFS of R/M NPC patients compared to placebo plus GP (NR vs 13.9 months) after a follow-up of 15.5 months. Currently, there are lots of clinical trials testing checkpoint inhibitors for NPC (Table 1).

**Table 1 Immunotherapies for NPC treatment**

| Target | Effects | Treatment | NCT number |
|--------|---------|-----------|------------|
| PD-1   | Bypass immune checkpoint | Nivolumab, Pembrolizumab, Toripalimab, Pem-pulimab, Camrelizumab, Sintilimab, Tislelizumab, Treprilimab, SHR-1701 | NCT02054806 [7], NCT02339558 [40], NCT02915432 [116], NCT03581786 [6], NCT03558191, NCT03267498, NCT03544099, NCT03734809, NCT03707509, NCT03925090, NCT03929486, NCT04282070, NCT04376866, NCT0447612, NCT04421460, NCT04534885, NCT04726810, NCT04833257, NCT04917770, NCT04944914, NCT04978012, NCT3707509, NCT05020925, NCT05097209, NCT05341193, NCT04282070, NCT05020925, NCT04562441, NCT04220307, NCT04945421 |
| PD-L1  | Bypass immune checkpoint | SHR-1701, Avelumab | NCT04282070, NCT05020925, NCT04562441 |
| CTLA-4 & PD-1 | Bypass immune checkpoint | Ipilimumab, AK104, IBI310 | NCT03097939, NCT04202030, NCT04945421 |
| LMP2   | Direct cytotoxicity | LMP2 Antigen-specific TCR T cell | NCT03925896 |
| EBV    | Direct cytotoxicity | Autologous EBV specific Cytotoxic T cell | NCT03648697, NCT02287311, NCT02578641 [117] |
| TGF-β  | Direct cytotoxicity | TGF-β Resistant CTLs | NCT02065362 |

**Abbreviations:** CTLA-4 Cytotoxic T-lymphocyte antigen 4, PD-1 Programmed death 1, PD-L1 Programmed death ligand 1, CAR Chimeric antigen receptor
inhibitors alone or in combination with chemotherapy, radiotherapy and other immunotherapies (Table 1).

Another predominant regulatory checkpoint is TIM3. Inhibition of its ligand, Galectin-9, selectively revigorated infiltrating T lymphocytes by interfering with the interaction between PD-1 and TIM3 [79]. As Galectin-9 is specifically expressed by NPC cells, the TIM3/Galectin-9 interaction represents a promising approach to overcoming the resistance to the PD-1/PD-L1 inhibitors. The checkpoint receptor found on the surface of Tregs, CTLA4, binds CD80/86 on DCs to inhibit antigen presentation and secret IDO1 to induce the Treg proliferation [31]. The efficacy of the combination of ipilimumab/nivolumab in NPC are currently under investigation in phase II clinical trial (NCT03097939). Preliminary data up to November 2020 showed a partial response rate of 35% with a median response duration of 5.9 months, synergistically enhancing the efficacy of PD-1 monotherapy. Other therapeutic targets, such as LAG3, TIM3, and TIGIT, are currently immature compared to PD-1, but it is reasonable to assume that combining these molecules would be a more effective treatment option for patients with R/M NPC.

Expanding EBV/NPC-specific immune cells
An ongoing Phase III study (NCT02578641) using chemotherapy (Gemcitable & Carboplatin) followed by autologous, vitro-expanded EBV-specific cytotoxic T cell (EBVST) as first-line treatments for R/M NPC patients achieves a promising result with an overall response rate of 71.4% [117]. The individuals who received EBVST immunotherapy but showed no benefit were due to the expansion of mMDSCs leading to a dominant immune-suppressive effect, which points to a window of therapeutic opportunity [120]. Similar studies are being conducted using adoptive cellular-based immunotherapies such as EBV-TCR-T (NCT03648697) and LMP, BARF1 & EBNA1 Specific CTL (NCT02287311).

Other emerging cellular immunotherapy strategies, such as chimeric antigen receptor NK-Cell Immunotherapy (CAR-NK) and CAR-Macrophages (CAR-M), should be evaluated in NPC for their promising clinical efficacy in other cancers [121, 122]. Cancer vaccine, on the other hand, represents active immunotherapy that delivers tumor-specific antigens through APCs or viral vectors to improve immune system recognition. DCs expressing LMP2 and recombinant modified vaccinia Ankara vaccine (MVA) have been shown to be safe and well-tolerated [123]. Customized therapeutic vaccines can also be augmented by checkpoint inhibitor therapies [124]. Hence, future studies could consider combination immunotherapy to enhance the clinical responses, for example, immune checkpoint blockade combined with adoptive T-cell therapy [125, 126] or combining CAR T cells therapy combined with Ankara-oncolytic virus [127].

Targeting exosomes
There is substantial clinical evidence that exosomes can be used as biomarkers of disease, and a number of drugs have been developed to reduce the secretion of exosomes released by cancer cell and their effect on immune cells, such as RAB27A inhibitors, nSMase inhibitors, PPIs and calcium channel blockers [128]. Some of these inhibitors only affect exosomes released by tumor cells, which provides ideas for inhibiting the release of NPC-Exos. One of the most significant characteristics of NPC-Exos is the high level of miRNA content that governs the reprogramming of immune active factors and immune cell functions [129]. The use of exosome inhibitors or corresponding miRNA inhibitors might be able to block their effect of NPC cells on immune cells [130].

Besides focusing on NPC-Exos, exosomes secreted by immune cells can also serve as powerful anti-cancer weapons, such as NK-derived exosomes and Dendritic cell exosomes [131, 132]. In particular, exosomes derived from phosphor-antigen-expanded Vδ2-T cells can kill EBV-infected cells more efficiently [133]. In recent years, vaccines targeting exosomes have also been exploited, for example, dual-acting exosome vaccines for melanoma and lung cancer have shown the effectiveness in mouse models. However, exosomal vaccines have not been specifically tested in NPC [134]. But there are already many EBV vaccines that can be genetically engineered by exosomes to express specific antigens or target tumor cells to increase immunogenicity [135].

Targeting cytokine and chemokine
Immunomodulatory compounds such as cytokines and chemokines are being employed to reshape the tumor immune microenvironment. EBV-NPC cells produce high levels of TGF-β to promote a more aggressive malignant phenotype. TGF-β signaling is a crucial mediator not only of suppressive phenotypic transformation of tumor-infiltrating lymphocytes but also of remodulation in the stromal environment [136–138]. Given the axial role of the TGF-β signaling pathway in tumorigenesis, it can be regarded as an attractive target for EBV-NPC therapy. Currently, a clinical trial targeting TGF-β resistant T cells is being explored (NCT02065362).

Many NPC patients are accompanied by high EGFR expression, which often predicts an aggressive phenotype. LMP-1 can induce the expression and activation of EGFR and its ligand TGF-α in epithelial cells. Numerous studies have indicated that EGFR signaling plays a vital role in NPC pathogenesis [139–145]. LMP1 can also activate the insulin-like
growth factor 1 receptor (IGF1R), which promotes epithelial cell carcinogenesis and cause excessive anti-autophagic signaling to suppress anticancer immunosurveillance. It may constitute a druggable target for NPC in combination with chemo-immunotherapies [146, 147]. Altogether, further investigations on molecular targets are warranted for the treatment and management of NPC.

Conclusions
A deeper understanding of the crosstalk between the immune system and NPC that leads to suppression of anti-tumor response will greatly aid in developing more effective therapies. The identification of cytokines, immunosuppressive cell subpopulations and checkpoint pathways has allowed many immunotherapeutic drugs to be tested in clinical trials and hopefully used in clinical practice. The heterogeneity and complexity of advanced NPCs undoubtedly require a combination of these drugs to establish durable, lifelong immunity. In addition, consideration must be given to the optimal dose needed to establish durable tumor control while minimizing adverse events. Also, the unique characteristics of each NPC patient must be determined before suggesting the importance of selecting an optimal combination that maximizes PFS and minimizes toxicity.

Abbreviations
R/M NPC: Recurrent or metastatic NPC; EBV: Epstein-Barr virus; NK cells: Natural killer cells; MDSCs: Myeloid-derived suppressor cells; TME: Tumor microenvironment; ISG15: Interferon stimulating gene 15; IFI6: Interferon-inducible killer cells; IFN: Interferon-inducible protein 6; IFI44L: Interferon-inducible protein 44; ITIM3: Interferon-induced transmembrane protein 3; FGF: Fibroblast growth factor; TLRs: Tertiary lymphoid structures; APCs: Antigen-presenting cells; CAFs: Cancer-associated fibroblasts; PD-1/PD-L1: Programmed death-1/programmed death ligand-1; CTLA4: Cytotoxic T-lymphocyte antigen 4; TIM3: T cell immunoreceptor with Ig and ITIM domains; miRNAs: MicroRNAs; IncRNA: Long non-coding RNA; HLA: Human leucocyte antigen; HMC: Major histocompatibility complex; MIC: MHC class 1 molecular associated protein A/B; HIF-1: Hypoxia-inducible factor-1; EBNA: Epstein-Barr virus nuclear antigen; LMP: Latent membrane protein; FAs: Fatty acids; RIP3: Receptor interacting protein 3; IP-10: Interferon-inducible protein-10; MIP-3α: Macrophage inflammatory protein-3α; GM-CSF: Granulocyte–macrophage colony-stimulating factor.

Acknowledgements
We would like to thank Figdraw (www.figdraw.com) for its help in creating the figures.

Authors’ contributions
YJY drafted the manuscript and prepared the manuscript for submission. HMY conceived this work. All authors read and approved the final draft.

Funding
Not applicable.

Availability of data and materials
Not applicable.

Declarations
Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests. Figures were created by Figdraw (www.figdraw.com).

Author details
1 Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China. 2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China. 3 Shanghai Key Laboratory of Radiation Oncology, Shanghai 200032, China.

Received: 26 May 2022 Accepted: 1 August 2022 Published online: 13 August 2022

References
1. Li YY, Chung GTY, Lui VWY, To K-F, Ma BBY, Chow C, Woo JKS, Yip KY, Seo J, Hui EP, et al. Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations. Nat Commun. 2017;8:14121.
2. Lin D-C, Meng X, Hazawa M, Nagata Y, Varela AM, Xu L, Sato Y, Liu L-Z, Ding L-W, Sharma A, et al. The genomic landscape of nasopharyngeal carcinoma. Nat Genet. 2014;47(8):866–71.
3. Chen Y-P, Yin J-H, Li W-F, Li H-J, Chen D-P, Zhang C-J, Lv J-W, Wang Y-Q, Li X-M, Li J-Y, et al. Single-cell transcriptomics reveals regulators underlying immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinoma. Cell Res. 2020;30(11):1024–42.
4. Zheng H, Dai W, Cheung AKL, Kan R, Wong BWY, Leong MML, Deng M, Kwok TKT, Chan J-YH, et al. Whole-exome sequencing identifies multiple loss-of-function mutations of NF-κB pathway regulators in nasopharyngeal carcinoma. Proc Natl Acad Sci U S A. 2016;113(40):11283–8.
5. Chen Y-P, Chan ATC, Le Q-T, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet (London, England). 2019;394(10192):64–80.
6. Mai H-Q, Chen Q-Y, Chen D, Hu C, Yang K, Wen J, Li J, Shi Y-R, Jin F, Xu R, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and FASL promote tumor cell death and are correlated with tumor aggressiveness in nasopharyngeal carcinoma. Cell Physiol Biochem. 2020;56(4):1556–66.
7. Hsu C, Lee S-H, Ejadi S, Even C, Cohen RB, Le Tourneau C, Mehnert JM, Alzaga A, van Brummelen EMJ, Saraf S, et al. Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study. J Clin Oncol. 2017;35(36):4050–6.
8. Damania B, Munz C. Immune checkpoint inhibitors that predispose to pathologies by human oncoepidemiology and immune system abnormalities. FEMS Microbiol Rev. 2019;43(2):181–92.
9. Yang RC, Langerod A, Le Q-T, Cella M, Seo J, Hui EP, et al. Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations. Nat Commun. 2017;8:14121.
10. Chen KA, Wong JHS, Chin C, Lam W, Chan SL, Chan SWL, Mak C, Tse IOI, Leung SYM, et al. Analysis of plasma Epstein-barr virus DNA to screen for nasopharyngeal cancer. N Engl J Med. 2017;377(6):513–22.
11. Gong L, Kwong DL-W, Dai W, Wu P, Li S, Yan Q, Zhang Y, Zhang B, Fang X, Liu J, et al. Comprehensive single-cell sequencing reveals the stromal dynamics and tumor-specific characteristics in the microenvironment of nasopharyngeal carcinoma. Nat Commun. 2021;12(1):1540.
12. Young LS, Richardson AB. Epstein-Barr virus 40 years on. Nat Rev Cancer. 2004;4(10):757–68.
13. Tsao SW, Yip YL, Tsang CM, Pang PS, Lau VMY, Zhang G, Lo KW. Etiological factors of nasopharyngeal carcinoma. Oral Oncol. 2014;50(5):330–8.
14. Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, Rosenberg SA. Tumor antigen-specific CD8 T cells infiltrating...
the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009;114(13):1537–44.

15. Philip M, Fairchild L, Sun L, Horste EL, Camara S, Shahkiba M, Scott AC, Viale A, Lauer P, Menghout T, et al. Chromatin states define tumour-specific T cell dysfunction and reprogramming. Nature. 2017;545(7655):452–6.

16. Wang Y, Swiecki M, Cellia M, Alber G, Schreiber RD, Gillilan S, Colonna M. Timing and magnitude of type I interferon responses by distinct sensors impairs CD8 T cell exhaustion and chronic viral infection. Cell Host Microbe. 2012;11(6):631–42.

17. Bhat P, Leggett G, Waterhouse N, Frazer IH. Interferon-γ derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity. Cell Death Dis. 2017;8(6):e2836.

18. Williams LR, Quinn LL, Rowe M, Zhu J. Induction of the lytic cycle sensitizes Epstein-Barr virus-infected B cells to NK cell killing that is counteracted by virus-mediated NK cell evasion mechanisms in the late lytic cycle. J Virol. 2016;90(2):749–58.

19. Johansson-Percival A, He B, Li Z-J, Kjellén A, Russell K, Li J, Larma I, Ganss K, Mrizak D, Martin N, Barjon C, Jimenez-Pailhes A-S, Mustapha R, Niki T, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541–50.

20. Cheng S, Li Z, He J, Fu S, Duan Y, Zhou Q, Yan Y, Liu X, Liu F, et al. Epstein-Barr virus noncoding RNAs from the extracellular vesicles of nasopharyngeal carcinoma (NPC) cells promote angiogenesis via TLR3/RIG-I-mediated VCAM-1 expression. Biochim Biophys Acta Mol Basis Dis. 2019;1865(6):1201–13.

21. Lu Y, Qin Z, Wang J, Zheng X, Li J, Wei L, Peng Q, Zheng Y, Ou C, et al. Epstein-Barr Virus-Barr-TAT-R3p inhibits the IgK-I pathway. J Innate Immun. 2017;9(6):574–86.

22. Ge J, Wang J, Xiong F, Jiang X, Zhu K, Wang Y, Mo Y, Gong Z, Zhang S, He Y, et al. Epstein-Barr virus-encoded circular RNA circBART2.2 promotes immune escape of nasopharyngeal carcinoma by regulating PD-L1 expression. Nat Commun. 2018;9(1):3761.

23. Toyokawa K, Furukawa Y, Terajima M, Kikuchi K, Sato Y, Kato Y, et al. Epstein-Barr virus-encoded microRNA circBART2.2 targets tumor necrosis factor receptor 1 via NF-κB signaling and promotes progression of nasopharyngeal carcinoma. Sci Rep. 2017;7(1):17810.

24. Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541–50.

25. Kim J, Kim J, Lee J, Kim C, et al. Epstein-Barr virus infection imprints a unique immunological signature on nasopharyngeal carcinoma. J Natl Cancer Inst. 2020;112(7):1412–8.

26. Kim J. Epstein-Barr virus and nasopharyngeal carcinoma. J Natl Cancer Inst. 2020;112(7):1412–8.

27. Zhao S, Li Y, Guo Q, et al. Epstein-Barr virus infection induces the expression of immune checkpoint molecules in nasopharyngeal carcinoma cells. J Transl Med. 2020;18(1):211.

28. Kim J, Kim J, Lee J, Kim C, et al. Epstein-Barr virus infection imprints a unique immunological signature on nasopharyngeal carcinoma. J Natl Cancer Inst. 2020;112(7):1412–8.

29. Kim J, Kim J, Lee J, Kim C, et al. Epstein-Barr virus infection imprints a unique immunological signature on nasopharyngeal carcinoma. J Natl Cancer Inst. 2020;112(7):1412–8.

30. Kim J, Kim J, Lee J, Kim C, et al. Epstein-Barr virus infection imprints a unique immunological signature on nasopharyngeal carcinoma. J Natl Cancer Inst. 2020;112(7):1412–8.

31. Kim J, Kim J, Lee J, Kim C, et al. Epstein-Barr virus infection imprints a unique immunological signature on nasopharyngeal carcinoma. J Natl Cancer Inst. 2020;112(7):1412–8.

32. Kim J, Kim J, Lee J, Kim C, et al. Epstein-Barr virus infection imprints a unique immunological signature on nasopharyngeal carcinoma. J Natl Cancer Inst. 2020;112(7):1412–8.

33. Kim J, Kim J, Lee J, Kim C, et al. Epstein-Barr virus infection imprints a unique immunological signature on nasopharyngeal carcinoma. J Natl Cancer Inst. 2020;112(7):1412–8.

34. Kim J, Kim J, Lee J, Kim C, et al. Epstein-Barr virus infection imprints a unique immunological signature on nasopharyngeal carcinoma. J Natl Cancer Inst. 2020;112(7):1412–8.

35. Kim J, Kim J, Lee J, Kim C, et al. Epstein-Barr virus infection imprints a unique immunological signature on nasopharyngeal carcinoma. J Natl Cancer Inst. 2020;112(7):1412–8.

36. Kim J, Kim J, Lee J, Kim C, et al. Epstein-Barr virus infection imprints a unique immunological signature on nasopharyngeal carcinoma. J Natl Cancer Inst. 2020;112(7):1412–8.

37. Kim J, Kim J, Lee J, Kim C, et al. Epstein-Barr virus infection imprints a unique immunological signature on nasopharyngeal carcinoma. J Natl Cancer Inst. 2020;112(7):1412–8.

38. Kim J, Kim J, Lee J, Kim C, et al. Epstein-Barr virus infection imprints a unique immunological signature on nasopharyngeal carcinoma. J Natl Cancer Inst. 2020;112(7):1412–8.

39. Kim J, Kim J, Lee J, Kim C, et al. Epstein-Barr virus infection imprints a unique immunological signature on nasopharyngeal carcinoma. J Natl Cancer Inst. 2020;112(7):1412–8.

40. Kim J, Kim J, Lee J, Kim C, et al. Epstein-Barr virus infection imprints a unique immunological signature on nasopharyngeal carcinoma. J Natl Cancer Inst. 2020;112(7):1412–8.

41. Kim J, Kim J, Lee J, Kim C, et al. Epstein-Barr virus infection imprints a unique immunological signature on nasopharyngeal carcinoma. J Natl Cancer Inst. 2020;112(7):1412–8.

42. Kim J, Kim J, Lee J, Kim C, et al. Epstein-Barr virus infection imprints a unique immunological signature on nasopharyngeal carcinoma. J Natl Cancer Inst. 2020;112(7):1412–8.

43. Kim J, Kim J, Lee J, Kim C, et al. Epstein-Barr virus infection imprints a unique immunological signature on nasopharyngeal carcinoma. J Natl Cancer Inst. 2020;112(7):1412–8.

44. Kim J, Kim J, Lee J, Kim C, et al. Epstein-Barr virus infection imprints a unique immunological signature on nasopharyngeal carcinoma. J Natl Cancer Inst. 2020;112(7):1412–8.

45. Kim J, Kim J, Lee J, Kim C, et al. Epstein-Barr virus infection imprints a unique immunological signature on nasopharyngeal carcinoma. J Natl Cancer Inst. 2020;112(7):1412–8.

46. Kim J, Kim J, Lee J, Kim C, et al. Epstein-Barr virus infection imprints a unique immunological signature on nasopharyngeal carcinoma. J Natl Cancer Inst. 2020;112(7):1412–8.

47. Kim J, Kim J, Lee J, Kim C, et al. Epstein-Barr virus infection imprints a unique immunological signature on nasopharyngeal carcinoma. J Natl Cancer Inst. 2020;112(7):1412–8.

48. Kim J, Kim J, Lee J, Kim C, et al. Epstein-Barr virus infection imprints a unique immunological signature on nasopharyngeal carcinoma. J Natl Cancer Inst. 2020;112(7):1412–8.

49. Kim J, Kim J, Lee J, Kim C, et al. Epstein-Barr virus infection imprints a unique immunological signature on nasopharyngeal carcinoma. J Natl Cancer Inst. 2020;112(7):1412–8.

50. Kim J, Kim J, Lee J, Kim C, et al. Epstein-Barr virus infection imprints a unique immunological signature on nasopharyngeal carcinoma. J Natl Cancer Inst. 2020;112(7):1412–8.
52. Dai W, Zheng H, Cheung AKL, Tang CS-m, Ko JMY, Wong BWY, Leong MML, Sham PC, Cheung F, Kwong DL-W, et al. Whole-exome sequencing identifies MST1R as a genetic susceptibility gene in nasopharyngeal carcinoma. Proc Natl Acad Sci USA. 2016;113(12):3317–22.

53. Yao Y, Minter HA, Chen X, Reynolds GM, Bromley M, Arrand JR. Heterogeneity of HLA and EBER expression in Epstein-barr virus-associated nasopharyngeal carcinoma. Int J Cancer. 2000;86(6):949–55.

54. Albanese M, Tagawa T, Bouvet M, Malig I, Lutter D, Hoser J, Hastedt M, Hayes M, Sugden B, Martin L, et al. Epstein-barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells. Proc Natl Acad Sci USA. 2016;113(42):E6467–75.

55. The Taylor GS, Long HM, Brooks JM, Richardson AB, Hislop AD. The immunology of Epstein-barr virus-induced disease. Annu Rev Immunol. 2015;33:787–821.

56. Singh S, Banerjee S. Downregulation of HLA-ABC expression through promoter hypermethylation and demethylation of MIC-A/B surface expression in LMP2A-positive epithelial carcinoma cell lines. Sci Rep. 2020;10(1):5145.

57. Whiteside TL. Exosomes and tumor-mediated immune suppression. J Clin Invest. 2016;126(4):1216–23.

58. Verweij FJ, de Heus C, Kroeze S, Cai H, Kieff E, Piersma SR, Jimenez CR, Meckes DG, Shair KHY, Marquitz AR, Kung C-P, Edwards RH, Raab-Traub N. Human tumor virus utilizes exosomes for intercellular communication. Proc Natl Acad Sci USA. 2010;107(47):20370–5.

59. Aga M, Benztl GL, Raffa S, Tormi MR, Kondo S, Wakisaka N, Yoshizaki T, Pagano JS, Shackelford J. Exosomal HIF1α supports invasive potential of nasopharyngeal carcinoma-associated LMP1-positive exosomes. Oncogene. 2014;33(37):4613–22.

60. Tsai C-Y, Sakakibara S, Yasui T, Minamitani T, Okuzaki D, Kikutani H. Wu X, Zhou Z, Xu S, Liao C, Chen X, Li B, Peng J, Li D, Yang L. Exosome derived from nasopharyngeal carcinoma. Can Lett. 2020;478:93–106.

61. Wang X, Xiang Z, Tsao GS-W, Tu W. Exosomes derived from nasopharyngeal carcinoma cells induce IL-6 production from macrophages to promote tumorigenesis. Cell Mol Immunol. 2021;18(2):501–3.

62. Ye S-B, Zhang H, Cai T-T, Liu Y-N, Ni J-J, He J, Peng J-Y, Chen Q-Y, Mai H-Q, Zhang C-X, Cui J, Zhang Y, Yang B, Sun H, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. 2018;560(7718):382–6.

63. Poggio M, Hu T, Pai C-C, Chu B, Belair CD, Chang A, Montabana E, Lang UE, Fu Q, Fong L et al: Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory. Cell. 2019;177(2):414–427.e113.

64. Theodorakis M-N, Yerneni SS, Hoffmann TK, Gooding WE, Whiteside TL. Exosomal PD-L1 exosomes in plasma of head and neck cancer patients. Clin Cancer Res. 2018;24(4):896–905.

65. Theodorakis M-N, Yerneni S, Gooding WE, Ohr J, Clump BA, Bauman JE, Ferris RL, Whiteside TL. Circulating exosomes measure responses to therapy in head and neck cancer patients treated with cetuximab, ipilimumab, and IMRT. Oncoimmunology. 2019;8(7):1593805.

66. Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, Zheng XX, Strom TB, Kuchroo V. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nature. 2018;560(7718):382–6.

67. Chang Y-L. The immunologic advantage of recurrent nasopharyngeal carcinoma from the viewpoint of Galexin-9-Tim-3-related changes in the tumour microenvironment. Sci Rep. 2017;7(1):10349.

68. Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, Yu Z, Yang J, Wang B, Sun H, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. 2018;560(7718):382–6.

69. Kang K-P, Chang Y-T, Wu C-C, Liu Y-L, Chen M-C, Tsang N-M, Hsu C-L, Chang Y-S, Yu J-S. Multiplexed immunobead-based profiling of cytokine markers for detection of nasopharyngeal carcinoma and prognosis of patient survival. Head Neck. 2011;33(6):866–77.

70. Huang SCM, Tsao SW, Tsang CM. Interplay of Viral Infection, Host Cell Factors and Tumor Microenvironment in the Pathogenesis of Nasopharyngeal Carcinoma. Cancers. 2018;10(4):106.

71. Wang X, Yang B, She Y, Ye Y. The IncRNA TPT3-AS1 promotes ovarian cancer cell proliferation and metastasis via modulation of MMP2 and MMP9. J Cell Biochem. 2018;119(9):7790–9.
92. Liu W-I, Lin Y-H, Xiao H, Xing S, Chen H, Chi P-d, Zhang G. Epstein-Barr virus infection induces indoleamine 2,3-dioxygenase expression in human monocyte-derived macrophages through p38/mitogen-activated protein kinase and NF-κB pathways: impairment in T cell functions. J Virol. 2014;88(12):6660–71.

93. Chang CH, Qi J, O'Sullivan D, Buck MD, Noguchi T, Curtis JD, Chen Q, Gindin M, Gubin MM, van der Windt GJ, et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell. 2015;162(6):1229–41.

94. Ganesan K, Nikkanen J, Man K, Leong YA, Sogawa Y, Maschek A, Reinfeld BI, Madden MZ, Wolf MM, Chytil A, Bader JE, Patterson AR, Sugiyama S, Czabotar PE, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, Schmierer K, Whetstone RD, et al. Metabolic stress drives loss of T stability in glycolysis-low tumours. Nature. 2021;591(7851):652–8.

95. Xie G, Dong H, Li Q, Xu N, Hu X-C, Liao W, Jiang Y, Lin X-Y, Zhang Q-Y, et al. Efficacy, safety, and correlative biomarkers of topolipam in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical Trial (POLARIS-02). J Clin Oncol. 2021;39(7):704–12.

96. Zhang W, Wang G, Xu Z-G, Tu H, Hu F, Dai J, Zhang Y, Chen Y, Lu Y, Zeng X, et al. CAR-NK cells: a promising approach? Can Res. 2020;80(1):17–22.

97. Fan T, Sun G, Sun X, Zhao L, Zhong R, Peng Y. Tumor Energy Metabolism and Potential of 3-Bromopyruvate as an Inhibitor of Aerobic Glycolysis: Implications in Tumor Treatment. Cancers. 2019;11(3):317.

98. Zhang H, Lu J, Zhang G, Lu A. Advances in the discovery and Potential of 3-Bromopyruvate as an Inhibitor of Aerobic Glycolysis: Implications in Tumor Treatment. Cancers. 2019;11(3):317.

99. Afuso N, Zappasodi R, Serganova I, Cohen IJ, Maeda M, Shindo M, Sensabaugh G, et al. Inhibiting extracellular vesicles formation and release: a review of EV inhibitors. J Extracell Vesicles. 2020(9)(1):1703244.

100. Fan T, Sun G, Sun X, Zhao L, Zhong R, Peng Y. Tumor Energy Metabolism and Potential of 3-Bromopyruvate as an Inhibitor of Aerobic Glycolysis: Implications in Tumor Treatment. Cancers. 2019;11(3):317.

101. Afuso N, Zappasodi R, Serganova I, Cohen IJ, Maeda M, Shindo M, Sensabaugh G, et al. Inhibiting extracellular vesicles formation and release: a review of EV inhibitors. J Extracell Vesicles. 2020(9)(1):1703244.
132. Pitt JM, André F, Amigorena S, Soria J-C, Eggermont A, Kroemer G, Zitvogel L. Dendritic cell-derived exosomes for cancer therapy. J Clin Investig. 2016;126(4):1224–32.

133. Wang X, Xiang Z, Liu Y, Huang C, Pei Y, Wang X, Zhi H, Wong WH, Wei H, Ng IO et al: Exosomes derived from Vdelta2-T cells control Epstein-Barr virus-associated tumors and induce T cell antitumor immunity. Sci Transl Med. 2020;12(563):eaaz3426.

134. Xu Z, Zeng S, Gong Z, Yan Y. Exosome-based immunotherapy: a promising approach for cancer treatment. Mol Cancer. 2020;19(1):160.

135. Liu H, Chen H, Liu Z, Le Z, Nie T, Qiao D, Su Y, Mai H, Chen Y, Liu L. Therapeutic nanovaccines sensitize EBV-associated tumors to checkpoint blockade therapy. Biomaterials. 2020;255:120158.

136. Pickup M, Novitskiy S, Moses HL. The roles of TGFbeta in the tumour microenvironment. Nat Rev Cancer. 2013;13(11):788–99.

137. Zhang L, Maclisaac KD, Zhou T, Huang PY, Xin C, Dobson JR, Yu K, Chiang DY, Fan Y, Pelletier M, et al. Genomic analysis of nasopharyngeal carcinoma reveals TME-based subtypes. Mol Cancer Res. 2017;15(12):1722–32.

138. Li JP, Wu CY, Chen MY, Liu SX, Yan SM, Kang YF, Sun C, Grandis JR, Zeng MS, Zhong Q, PD-1(-)(CXCR5(-))CD4(+)(Th-CXCL13(+)Th cells) into tertiary lymphoid structures of nasopharyngeal carcinoma. J Immunother Cancer. 2021;9(7):e002101.

139. Xia W-X, Liang H, Lu X, Wang L, Qian C-N, Ye Y-F, Ke L-R, Qiu W-Z, Yu Y-H, Huang X-J, et al. Combining cetuximab with chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma: a propensity score analysis. Oral Oncol. 2017;67:167–74.

140. Li Y, Chen Q-Y, Tang L-Q, Liu L-T, Guo S-S, Guo L, Mo H-Y, Chen M-Y, Guo X, Cao K-J, et al. Concurrent chemoradiotherapy with or without cetuximab for stage II to IVB nasopharyngeal carcinoma: a case-control study. BMC Cancer. 2017;17(1):567.

141. Xu T, Liu Y, Dou S, Li F, Guan X, Zhu G. Weekly cetuximab concurrent with IMRT aggravated radiation-induced oral mucositis in locally advanced nasopharyngeal carcinoma: results of a randomized phase II study. Oral Oncol. 2015;51(9):875–9.

142. You R, Hua Y-J, Liu Y-P, Yang Q, Zhang Y-N, Li J-B, Li C-F, Zou X, Yu T, Cao J-Y, et al. Concurrent chemoradiotherapy with or without Anti-EGFR-Targeted treatment for stage II-IVB nasopharyngeal carcinoma: retrospective analysis with a large cohort and long follow-up. Theranostics. 2017;7(8):2314–24.

143. You R, Sun R, Hua Y-J, Li C-F, Li J-B, Zou X, Yang Q, Liu Y-P, Zhang Y-N, Yu T, et al. Cetuximab or nimotuzumab plus intensity-modulated radiotherapy versus cisplatin plus intensity-modulated radiotherapy for stage II-IVB nasopharyngeal carcinoma. Int J Cancer. 2017;141(6):1265–76.

144. Huang J-F, Zhang F-Z, Zou Q-Z, Zhou L-Y, Yang B, Chu J-J, Yu J-H, Zhang H-W, Yuan X-P, Tai G-M, et al. Induction chemotherapy followed by concurrent chemoradiation and nimotuzumab for locoregionally advanced nasopharyngeal carcinoma: preliminary results from a phase II clinical trial. Oncotarget. 2017;8(2):2467–56.

145. He X, Xu J, Guo W, Jiang X, Wang X, Zong D. Cetuximab in combination with chemoradiation after induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma: preliminary results. Future Oncol. 2013;9(10):1459–67.

146. Tworkoski K, Raab-Traub N. LMP1 promotes expression of insulin-like growth factor 1 (IGF1) to selectively activate IGF1 receptor and drive cell proliferation. J Virol. 2015;89(5):2590–602.

147. Wu Q, Tian A-L, Li L, Leduc M, Forveille S, Hamley P, Galloway W, Xie W, Liu P, Zhao L et al: IGF1 receptor inhibition amplifies the effects of cancer drugs by autophagy and immune-dependent mechanisms. J Immunother Can. 2021;9(6):e002722.